fashion -WSS

fashion

author：comprehensive 2025-09-28 03:36:38 - browse：4265

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The thinking behind the controversial eating disorder chatbot Tessa

explore

leisure time

WSS

Biden administration plans revamp of organ transplant system

Can medical device makers keep up in the race to treat obesity?

Novo pauses ads for weight loss drug Wegovy amid demand

Biogen shutters digital health group, ends Apple study, in cost cutting move

Biogen nominates mother of director’s child to replace him on board

Health tech startups drop sharply from 2021 highs

explore

fashion

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The thinking behind the controversial eating disorder chatbot Tessa

Peter Hotez and the public health issue of online harassment

Menendez indictment could see pharma lose a key ally

United colonoscopy coverage change 'may cost lives,' doctors say

Reanimated hearts work just as well for transplants, study finds

Medical records are filled with copy

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biden administration plans revamp of organ transplant system

knowledge

Address the ethical violations that led to 'Three Identical Strangers'

Sudafed saga points to U.S. issues with evaluating older drugs

Medicare drug price negotiation program allowed for now

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

explore

hotspot

leisure time

explore